Descrizione del progetto
Diagnosi più rapide della resistenza agli antimicrobici
L’impiego sconsiderato di antibiotici è responsabile della comparsa della resistenza antimicrobica provocata da batteri che non è possibile uccidere con i farmaci esistenti. Questo fenomeno minaccia le procedure ospedaliere di routine e, ogni anno, porta a un numero considerevole di decessi. L’obiettivo del progetto Nanosynex, finanziato dall’UE, è proporre una tecnologia rivoluzionaria basata sulla microfluidica in grado di accorciare nettamente i tempi di elaborazione dei campioni, fornendo una diagnosi più rapida di questa condizione. L’introduzione del dispositivo nella pratica diagnostica di routine aiuterà i medici a prendere decisioni più informate e precise sulle terapie antibiotiche da eseguire per curare i propri pazienti.
Obiettivo
Antimicrobial Resistance (AMR) has been declared as one of today’s biggest global threats as 700,000 people die due AMR.
Inappropriate antibiotic use is widespread. In the general practice, physicians commonly use empirical antibiotic therapy (highly inaccurate), since AST results take too long. Nanosynex product provides a revolutionary ultra-fast AST technology that will disrupt the market by cutting time to results in more than half (from 9 – the fastest - to 4 hours). This will allow physicians to get same-day results (i.e. in less than 5 hours) for AST, a unique feature that will save at least one day of hospitalization per patient and help reducing the spread of resistant bacteria. A successful validation through this Phase-1 of the technology and our revenue models will be fundamental to demonstrate evidence of user satisfaction A successful validation through this Phase-1 of the technology and our revenue models will be fundamental to demonstrate evidence of user satisfaction. Nanosynex Ltd is an Israeli start-up providing health-care systems with a rapid microfluidic diagnostic solution for faster and personalised antibiotic treatment. The company intends to scale up in the European market first, thanks to its strategic partnership with Biosynex, a leading French rapid diagnostic test (RDT) company that has an established distribution network in Europe, Middle East and Africa (60+ countries). Afterwards, Nanosynex will expand internationally. Nanosynex forecast to generates 14.7M€ , and and at EBITDA of 3.4M€ by 2024
Campo scientifico
- natural sciencesbiological sciencesmicrobiologybacteriology
- social scienceseconomics and businessbusiness and managementbusiness models
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibiotics
- engineering and technologymedical engineeringmedical laboratory technologydiagnostic technologies
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance
Programma(i)
Argomento(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-SMEInst-2018-2020-1
Meccanismo di finanziamento
SME-1 - SME instrument phase 1Coordinatore
5126112 Bnei Brak
Israele
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.